Nexell Therapeutics Inc.

Other

Baxter Healthcare Inc.

Kristen L Unverzagt

Stephen L Smith

Dennis E Van Epps

James G Bender

Phillip B Maples

James Bender

Jeffrey A Martinson

Orrin D Mitsven, Jr

Maureen Loudovaris

A composition comprising genetically altered human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% human myeloblasts and promyelocytes, which have been derived from neutrophil progenitor cells obtained from peripheral blood, bone marrow or cord blood, and less than about 5% colony forming units (CFU) of at least about 50 cells is provided. An alternative composition comprising genetically altered human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% CD15+CD11b- cells and less than about 5% colony forming units (CFU) of at least about 50 cells also is provided, wherein at least about 60% of the CD15+CD11b- cells are myeloblasts and promyelocytes.

In vitro-derived genetically altered human neutrophil precursor cells

The present invention provides a composition of human neutrophil precursor cells having at least 37% myeloblasts and promyeloblasts. Also provided are hematopoietic cell suspensions that have human neutrophil precursor cells and at least one hematopoietic growth factor.

In-vitro-derived human neutrophil precursor cells

A suspension comprising human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% human myeloblasts and promyeclocytes, which have been derived from neutrophis progenitor cells obtained from peripheral blood, bone marrow or cord blood, and less than about 5% colony forming units (CFU) of at least about 50 cells is provided. An alternative suspension comprising human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% CD15+CD11b- cells and less than about 5% colony forming units (CFU) of at least about 50 cells also is provided, wherein at least about 60% of the CD15+CD11b- cells are myeloblasts and promyelocytes. The suspensions of the invention are useful in methods for increasing neutrophil populations in a patient having a reduced populations of neutrophils.

Method for increasing neutrophil populations using in vitro-derived

A composition of human neutrophil precursor cells is disclosed wherein at least 16% of the cells are human myeloblasts and promyelocytes. The myeloblasts and promyelocytes are derived from human neutrophil progenitor cells that were obtained from peripheral blood, bone marrow or cord blood. The neutrophil precursor cells contain less than 5% colony forming units. Also disclosed are human neutrophil precursor cells made up of about 16% CD15+CD11b- cells and less than 5% colony forming units and methods of preparing these compositions.

Method for the preparation of in vitro-derived human neutrophil

The present invention provides an apparatus for holding and carrying a plurality of flexible medical containers. The carrier has a rack having a plurality of plates positioned in parallel spaced relation, the plates defining a chamber between each pair of adjacent plates. A plurality of spacer assemblies each extend through the rack to connect the plates and to maintain their spaced relationship. The spacer assemblies are spaced along marginal edges of the rack to define two opposed end walls, a bottom, and an opening to the rack to allow access to each of the chambers. A flange extends from one of the plates and has a hole that allows the carrier to be suspended. The invention further provides for a system for transferring fluids and a method for mixing solutions using the carrier.

Growing community of inventors

Palatine, IL, United States of America

Kristen L Unverzagt